SAB Biotherapeutics (SABS) AI Stock Analysis

• Market Cap: $17.01M
• Dividend Yield: N/A
• Average Volume (3M): 63.64K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.74
• Revenue Growth: -85.48%
• EPS Growth: 45.13%
• Country: US
• Employees: 63
• Sector: Healthcare
• Sector Strength: 59
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 9,291,697
• 10 Day Avg. Volume: 21,357
• 30 Day Avg. Volume: 63,639
• PEG Ratio: 0.00
• Price to Book (P/B): -1.91K
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -449.21
• Enterprise Value/Market Cap: 259.45
• Enterprise Value/Revenue: 736.56
• Enterprise Value/Gross Profit: -3.09K
• Enterprise Value/Ebitda: -32.77
• 1Y Price Target: $12.33
• Price Target Upside: 621.05% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 49 Neutral
• Price Target: $2.00 ▲(16.96%Upside)

SAB Biotherapeutics struggles with significant financial challenges, weak valuation metrics, and ongoing losses, which weigh heavily on its overall score. The technical indicators offer a glimmer of positive momentum, but not enough to offset the substantial risks associated with its financial instability.

Positive Factors

Clinical Trials

SAB-142's encouraging Phase 1 safety and efficacy in healthy volunteers sets the stage for Phase 2b looking to modulate type 1 diabetes progression.

Dosing Regimen

SAB-142 has a potential competitive dosing regimen with 2-3 days dosing versus 12-14 days with teplizumab, which could be advantageous for outpatient settings.

Market Expansion

The company's plans to potentially pursue other indications for SAB-142 in different stages of type 1 diabetes suggest a broader market opportunity.

Mechanism of Action

SAB-142's multi-target mechanism of action has been clinically validated in type 1 diabetes through several successful clinical trials, further reducing development risk.

Safety Profile

Positive topline data readout showcased sustained immunomodulation and a clean safety profile, positioning SAB-142 as a potential new immunotherapy to prevent and control the progression of type 1 diabetes.

Negative Factors

SAB Biotherapeutics Business Overview & Revenue Model

Company Description

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.

How the Company Makes Money

SAB Biotherapeutics makes money primarily through the development and commercialization of its immunotherapy products. The company generates revenue by engaging in strategic partnerships and collaborations with pharmaceutical companies, government agencies, and other organizations to advance its therapeutic candidates. These partnerships often involve milestone payments, licensing fees, and royalties based on product sales. Additionally, SAB Biotherapeutics may receive funding from grants and government contracts to support the research and development of its antibody therapies. The company's revenue streams are significantly influenced by its ability to successfully bring its products to market and establish lucrative partnerships within the biotechnology sector.

SAB Biotherapeutics Financial Statement Overview

Summary

SAB Biotherapeutics faces significant financial challenges, including a dramatic decline in revenue and persistent losses. The cash flow issues and a high debt-to-equity ratio exacerbate concerns, although the balance sheet provides a modicum of stability.

Income Statement

SAB Biotherapeutics has experienced a significant decline in revenue over recent years, with total revenue falling from $60.88 million in 2021 to just $1.32 million in 2024. The company has maintained negative EBIT and net income, indicating ongoing operational challenges. Margins have remained weak, with a negative net profit margin, reflecting persistent losses.

Balance Sheet

The company's balance sheet shows a relatively high debt-to-equity ratio, indicating a reliance on debt financing. However, the equity ratio remains reasonable, suggesting some level of financial stability. Stockholders' equity has decreased over the years, which could be a concern if this trend continues.

Cash Flow

SAB Biotherapeutics has faced challenges in generating positive operating cash flow, with significant negative free cash flow in recent years. The company has also shown volatility in financing cash flows, suggesting potential difficulties in maintaining liquidity and funding operations.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
377.83K	1.32M	2.24M	23.90M	60.88M	55.24M
	Gross Profit
-1.43M	-3.47M	-1.51M	20.61M	59.22M	55.24M
	EBIT
-42.29M	-42.91M	-38.08M	-28.92M	-13.39M	20.56M
	EBITDA
-30.38M	-28.99M	-38.13M	-15.12M	-15.20M	21.14M
	Net Income Common Stockholders
-34.28M	-34.10M	-42.19M	-18.74M	-17.14M	20.12M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
12.85M	20.76M	56.57M	15.05M	33.21M	12.61M
	Total Assets
38.12M	44.20M	83.94M	50.90M	79.37M	56.54M
	Total Debt
6.78M	4.67M	5.91M	5.93M	6.74M	8.13M
	Net Debt
1.14M	-4.23M	-50.66M	-9.12M	-26.46M	-4.48M
	Total Liabilities
16.71M	18.23M	26.64M	19.85M	40.82M	17.53M
	Stockholders Equity
21.41M	25.97M	57.30M	31.06M	38.55M	39.01M
Cash Flow		Free Cash Flow
-31.62M	-34.63M	-25.32M	-7.19M	-7.19M	-2.73M
	Operating Cash Flow
-31.41M	-34.29M	-25.12M	3.76M	3.76M	10.00M
	Investing Cash Flow
24.07M	-11.96M	-152.70K	-10.94M	-10.94M	-12.72M
	Financing Cash Flow
-952.19K	-1.17M	66.77M	34.12M	34.12M	8.98M

SAB Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.71
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SABS, the sentiment is Negative. The current price of 1.71 is below the 20-day moving average (MA) of 1.83, above the 50-day MA of 1.65, and below the 200-day MA of 2.50, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 44.37 is Neutral, neither overbought nor oversold. The STOCH value of 42.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SABS.

SAB Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.38B	3.27	-45.10%	3.30%	16.81%	0.02%
SABS	49 Neutral	$17.01M	―	-92.35%	―	-85.48%	45.13%
BOLT	46 Neutral	$11.69M	―	-83.92%	―	-67.87%	0.40%
MRKR	44 Neutral	$18.10M	―	-97.30%	―	-3.23%	38.05%
IMNN	41 Neutral	$25.08M	―	-397.54%	―	―	24.16%
ERNA		$9.52M	―	-2264.31%	―	―	―
INAB	34 Underperform	$8.20M	―	-174.66%	―	―	38.53%